ArticleArchives of microbiology2026
Biocontrol mechanisms of a karstic cave-derived Streptomyces sp. GCAL-9 bioactive extract against Colletotrichum musae: insights into ergosterol pathway involvement and metabolomic profiling.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Anthracnose is a fungal disease associated with Colletotrichum members responsible for one of the major diseases that critically deteriorate fruit quality. Herein, we aimed to evaluate the biocontrol mechanism of the Streptomyces sp. GCAL-9 bioactive extract (BE9) against Colletotrichum musae. We also determined alterations in cell morphology, changes in membrane stability, and the effects on the expression of ergosterol biosynthesis-related genes. Additionally, we analyzed genomic and phylogenomic information. The strain GCAL-9 was initially isolated from a cave and evaluated for its antifungal activity against C. musae, and additionally against several phytopathogenic fungi. The minimal inhibitory concentration (MIC) of BE9 against C. musae conidial germination was 48 µg/mL, while the minimal fungicidal concentration (MFC) was 96 µg/mL. With an MFC/MIC ratio of 2, BE9 reduced fungal mycelial growth by 80% and spore germination by 75%. Regarding the effect of BE9 on the expression of ergosterol biosynthesis-related genes, it downregulated the transcription of Cmhmg1, the gene encoding a key enzyme in the mevalonate pathway. This downregulated effect on enzymatic biosynthesis of ergosterol suggest a disruption of the membrane integrity and viability of conidial cells, inducing morphological shrinkage and a contracted appearance. Furthermore, application of BE9 on banana surfaces infected with C. musae conidia prevented anthracnose progression, similarly to the chemical fungicide carbendazim. Untargeted metabolomic profiling of BE9 exposed the presumptive presence of enokipodin A, a sesquiterpene metabolite previously reported in fungal species. This study showed the identification of a potential novel species capable of producing extracellular secondary metabolites to control anthracnose-causing fungi that infect postharvest fruits.
Indexed as
Identifiers
42566000What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.